Data / Form D filings / Gen9, Inc.
Gen9, Inc.: Form D filings
Gen9, Inc., a biotechnology company in Cambridge, MA, filed 7 Form D notices with the SEC between 2009 and 2014. The latest, on July 30, 2014, reports $25 million sold of a $25 million offering to 4 investors.
Find out what Gen9, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 840 Memorial Drive, Fifth floor, Cambridge, MA, 01239
- Phone
- (617) 250-8433
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1465638
The full lists. Form D filings in Massachusetts: 1,533 rows, $76.65, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jul 30, 2014 | New notice | $25,000,000 | $25,000,000 | $0 | 4 | Jul 25, 2014 | sec.gov |
| May 7, 2013 | New notice | $21,000,000 | $21,000,000 | $0 | 43 | Apr 22, 2013 | sec.gov |
| May 22, 2012 | New notice | $2,000,000 | $395,000 | $1,605,000 | 3 | May 18, 2012 | sec.gov |
| Sep 9, 2011 | New notice | $9,591,568 | $1,550,001 | $8,041,567 | 19 | Aug 25, 2011 | sec.gov |
| Apr 28, 2011 | Amendment | $2,500,000 | $1,955,000 | $545,000 | 13 | Nov 15, 2010 | sec.gov |
| Feb 10, 2011 | New notice | $2,000,000 | $1,655,000 | $345,000 | 12 | Nov 15, 2010 | sec.gov |
| Jun 15, 2009 | New notice | $2,000,000 | $500,000 | $1,500,000 | 1 | Jun 1, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jennifer Camacho | Executive Officer | |
| Jacob Thaysen | Director | |
| Jeremy Wertheimer | Director | |
| David Stone | Executive Officer | |
| Kevin Munnelly | Executive Officer, Director | |
| Joseph Jacobson | Director | |
| James Hollenhorst | Director | |
| Drew Endy | Director | |
| Neil Cook | Director |
Other biotechnology companies in Massachusetts that filed recently
- Zai Lab Ltd $249.9 million · Nov 9, 2026
- AI3 Bio, Inc. offering · Nov 4, 2026
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
Every Form D from the week of Jul 28, 2014 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Gen9, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.